Department of Neurosurgery, Peking University International Hospital, Peking University Health Science Center, Peking University, Changping District, Beijing, 102206, China.
Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Int J Clin Oncol. 2020 Jul;25(7):1215-1222. doi: 10.1007/s10147-020-01685-y. Epub 2020 Apr 29.
Glioblastoma (GBM) is one of the most malignant neural tumors, and patients with GBM often die soon after the onset. The pathogenesis of GBM is very complicated, and there is no effective treatment for GBM. The current research results show that a variety of microRNA (miRNA) are involved in the regulation of GBM occurrence and development through specific signal pathways. Meanwhile, as a non-invasive biological indicator, there is an important clinical value of miRNA in the diagnosis and prognosis of GBM. The research of targeted miRNA treatment for GBM is still in the cell and animal model stage, although the basic research shows a good result, there is still a certain distance to the clinical application.
胶质母细胞瘤（GBM）是最恶性的神经肿瘤之一，GBM 患者通常在发病后很快死亡。GBM 的发病机制非常复杂，目前对 GBM 还没有有效的治疗方法。现有研究结果表明，多种 microRNA（miRNA）通过特定的信号通路参与 GBM 的发生和发展的调控。同时，miRNA 作为一种非侵入性的生物标志物，在 GBM 的诊断和预后中有重要的临床价值。针对 GBM 的 miRNA 靶向治疗的研究仍处于细胞和动物模型阶段，虽然基础研究结果良好，但距离临床应用仍有一定的距离。
